 | | PRD_002379 | | Name: | thiopeptide TP1 | | Formula: | C83 H108 N19 O17 S2 | | Definition date: | 2022-10-26 | | Last modified: | 2022-10-26 |
|
 | | PRD_002381 | | Name: | thiopeptide TP15 | | Formula: | C77 H115 N26 O17 S3 | | Definition date: | 2022-10-26 | | Last modified: | 2022-10-26 |
|
 | | PRD_002409 | | Name: | UDP-MurNAc-pentapeptide | | Formula: | C37 H58 N8 O26 P2 S | | Description: | Peptidoglycan precursor analogue | | Definition date: | 2022-10-26 | | Last modified: | 2022-10-26 |
|
 | | PRD_002097 | | Name: | [[[(4S)-5-[[(2S)-1-[[(2S)-5-[[azaniumylidene(azanyl)methyl]amino]-1-oxidanylidene-pentan-2-yl]amino]-3-methyl-1-oxidanylidene-butan-2-yl]amino]-5-oxidanylidene-4-[[(2S)-1-oxidanyl-1-oxidanylidene-3-phenyl-propan-2-yl]carbamoylamino]pentyl]amino]-azanyl-methylidene]azanium | | Formula: | C27 H46 N10 O6 | | Description: | Acts as a reversible inhibitor of serine/cysteine proteases and some trypsin-like serine proteases. | | Definition date: | 2013-08-07 | | Last modified: | 2022-10-20 |
|
 | | PRD_002471 | | Name: | N-{3-[(prop-2-yn-1-yl)oxy]propanoyl}-D-phenylalanyl-N-[(3S)-6-carbamimidamido-2-oxohexan-3-yl]-L-phenylalaninamide | | Formula: | C31 H40 N6 O5 | | Definition date: | 2022-10-12 | | Last modified: | 2022-10-12 |
|
 | | PRD_002472 | | Name: | N-{3-[(prop-2-yn-1-yl)oxy]propanoyl}-D-phenylalanyl-N-[(3S)-6-(carbamoylamino)-2-oxohexan-3-yl]-L-phenylalaninamide | | Formula: | C31 H39 N5 O6 | | Definition date: | 2022-10-12 | | Last modified: | 2022-10-12 |
|
 | | PRD_002509 | | Name: | Colistin | | Formula: | C52 H98 N16 O13 | | Definition date: | 2022-09-14 | | Last modified: | 2022-09-14 |
|
 | | PRD_002370 | | Name: | Taltirelin | | Formula: | C17 H24 N7 O5 | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002371 | | Name: | Endogenous Peptide Agonist TRH | | Formula: | C16 H23 N6 O4 | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002386 | | Name: | tert-butyl N-[3-(2-hydroxyethylcarbamoyl)-5-phenyl-thiophen-2-yl]carbamate | | Formula: | C18 H22 N2 O4 S | | Definition date: | 2022-08-31 | | Last modified: | 2022-08-31 |
|
 | | PRD_002490 | | Name: | Eptifibatide | | Formula: | C35 H49 N11 O9 S2 | | Definition date: | 2022-08-17 | | Last modified: | 2022-08-17 |
|
 | | PRD_002496 | | Name: | evybactin | | Formula: | C64 H91 N21 O21 | | Definition date: | 2022-08-17 | | Last modified: | 2022-08-17 |
|
 | | PRD_002491 | | Name: | Sa-D2 | | Formula: | C88 H122 N19 O23 S2 | | Definition date: | 2022-08-10 | | Last modified: | 2022-08-10 |
|
 | | PRD_002492 | | Name: | Sa-D3 | | Formula: | C87 H110 N18 O24 S | | Definition date: | 2022-08-10 | | Last modified: | 2022-08-10 |
|
 | | PRD_002367 | | Name: | ~{N}-[3-[3-(dimethylamino)propylamino]-3-oxidanylidene-propyl]-1-methyl-4-[3-[[1-methyl-4-[[1-methyl-4-[3-[[1-methyl-4-[(1-methylimidazol-2-yl)carbonylamino]pyrrol-2-yl]carbonylamino]propanoylamino]imidazol-2-yl]carbonylamino]pyrrol-2-yl]carbonylamino]propanoylamino]imidazole-2-carboxamide | | Formula: | C41 H55 N17 O8 | | Definition date: | 2022-08-03 | | Last modified: | 2022-08-03 |
|
 | | PRD_002384 | | Formula: | C58 H95 N15 O15 | | Definition date: | 2022-08-03 | | Last modified: | 2022-08-03 |
|
 | | PRD_002495 | | Name: | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | | Formula: | C21 H31 N3 O8 S | | Definition date: | 2022-05-04 | | Last modified: | 2022-05-04 |
|
 | | PRD_000468 | | Name: | Allosamidin | | Formula: | C25 H42 N4 O14 | | Definition date: | 2015-07-18 | | Last modified: | 2022-03-03 |
|
 | | PRD_000041 | | Name: | (2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3R,4R,5S)-4-(2-(3-AMINOPROPYLAMINO)ETHOXY)-5-((1R,2R,3S,5R,6S)-3,5-DIAM
INO-2-((2S,3R,4R,5S,6R)-3-AMINO-4,5-DIHYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-2-(
HYDROXYMETHYL)-TETRAHYDROFURAN-3-YLOXY)-TETRAHYDRO-2H-PYRAN-3,4-DIOL | | Formula: | C28 H57 N7 O14 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000042 | | Name: | (2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3R,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-DIAMINO-2-((2S,3R,4R,5S,6R)-3-AMINO-4
,5-DIHYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-2-(HYDROXYMETHYL)-4-(2-((R)-PIPERIDI
N-3-YLMETHYLAMINO)ETHOXY)-TETRAHYDROFURAN-3-YLOXY)-TETRAHYDRO-2H-PYRAN-3,4-DIOL | | Formula: | C31 H61 N7 O14 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000043 | | Name: | DOUBLY FUNCTIONALIZED PAROMOMYCIN PM-II-162 | | Formula: | C37 H65 N7 O16 | | Definition date: | 2017-07-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_002479 | | Name: | Cyclic Peptide Inhibitor ZO1-GLN-SER-TPO-45W-MLL | | Formula: | C34 H48 F3 N6 O14 P | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002486 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[([1,1'-biphenyl]-4-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C49 H67 N5 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002487 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[(1H-indol-3-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C45 H64 N6 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_000323 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-[(1S,2R,3R)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-N~4~-[2-(d
imethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C34 H53 N5 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
